Sage Journals: Discover world-class research

Abstract

Objective

To examine the prevalence of ultrarapid metabolizers of codeine among children in an ethnically diverse urban community.

Study Design

Cross-sectional study.

Setting

A tertiary care academic children’s hospital in the Bronx, New York.

Subjects and Methods

In total, 256 children with nonsyndromic congenital sensorineural hearing loss were analyzed. DNA was assessed for 63 previously described single-nucleotide polymorphisms (SNPs) and copy number variants (CNVs) known to alter the function and expression of the CYP2D6 gene primarily responsible for codeine metabolism. The rate of CYP2D6 metabolism was predicted based on participants’ haplotype.

Results

Ethnic distribution in the study subjects paralleled recent local census data, with the largest portion (115 children, 45.8%) identified as Hispanic or Latino. A total of 154 children (80.6%) had a haplotype that corresponds to extensive codeine metabolism, 18 children (9.42%) were identified as ultrarapid metabolizers (UMs), and 16 children (8.37%) were intermediate metabolizers. Only 3 children in our cohort (1.57%) were poor metabolizers. Patients identifying as Caucasian or Hispanic had an elevated incidence of UMs (11.3% and 11.2%, respectively) with extensive variability within subpopulations.

Conclusions

The clinically significant rate of ultrarapid metabolizers reinforces safety concerns regarding the use of codeine and related opiates. A patient-targeted approach using pharmacogenomics may mitigate adverse effects by individualizing the selection and dosing of these analgesics.

Keywords

cytochrome p450 pharmacogenomics ultrarapid metabolizer

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. FDA Drug Safety Communication: Codeine Use in Certain Children after Tonsillectomy and/or Adenoidectomy May Lead to Rare, but Life-Threatening Adverse Events or Death. MedWatch Safety Alert. Silver Spring, MD. August 15, 2012.

Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Codeine Use in Children: New Boxed Warning and Contraindication on Use after Tonsillectomy and/or Adenoidectomy. Retrieved from https://www.fda.gov/downloads/Drugs/DrugSafety/UCM339116.pdf.

Leppert

CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87:274-285.

Williams

Patel

Howard

RF.

Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth. 2002;89:839-845.

Crews

Gaedigk

Dunnenberger

et al . Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95:376-382.

Zhou

SF.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48:761-804.

Kirchheiner

Schmidt

Tzvetkov

et al . Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7:257-265.

Sistonen

Sajantila

Lao

Corander

Barbujani

Fuselli

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.

Gaedigk

Simon

Pearce

et al . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.

10.

Cai

Nikoloff

Pan

et al . CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006;6:343-350.

11.

US Census Bureau. QuickFacts Bronx County (Bronx Borough), New York 2010. Retrieved from https://www.census.gov/quickfacts/fact/table/bronxcountybronxboroughnewyork/PST045217.

12.

Cespedes-Garro

Naranjo

Rodrigues-Soares

et al . Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016;17:1707-1724.

13.

Cespedes-Garro

Naranjo

Ramirez

et al . Pharmacogenetics in Central American healthy volunteers: interethnic variability. Drug Metab Pers Ther. 2015;30:19-31.

14.

Samanich

Lowes

Burk

et al . Mutations in GJB2, GJB6, and mitochondrial DNA are rare in African American and Caribbean Hispanic individuals with hearing impairment. Am J Med Genet A. 2007;143A:830-838.

15.

Phillips

Veenstra

Oren

Lee

Sadee

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286:2270-2279.

16.

Evans

Relling

MV.

Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464-468.

17.

Shahabi

Dube

MP.

Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Int J Cardiol. 2015;184:772-795.

18.

Sohn

Croxford

Yates

Lucock

Kim

YI.

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004;96:134-144.

19.

Jamieson

Cresti

Bray

et al . Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics. 2011;21:808-819.

20.

Goetz

Rae

Suman

et al . Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312-9318.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

The Prevalence of Ultrarapid Metabolizers of Codeine in a Diverse Urban Population